Status:
WITHDRAWN
Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease
Lead Sponsor:
Leiden University Medical Center
Conditions:
Chronic Kidney Disease
Inflammation
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study in patients with stage 4 and 5 chronic kidney disease is to determine whether rosiglitazone can reduce inflammatory markers and to investigate its effect on intima media thic...
Detailed Description
This is a double-blind randomised placebo-controlled clinical multicenter trial in patients with stage 4 and 5 chronic kidney disease. Eligible patients in the outpatient kidney clinic and patients at...
Eligibility Criteria
Inclusion
- Written consent
- Over 18 years of age
- Stage 4 or 5 chronic kidney disease according the K/DOQI guidelines
Exclusion
- Life span of less than one year
- Alcohol abuse
- Transaminases \> 2.5 times the upper limit
- Diabetes mellitus
- Pregnancy
- Cardiac disease with marked limitation of functional capacity (NYHA III or IV)
- Use of immunosuppressant agents
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2009
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00169923
Start Date
April 1 2007
End Date
May 1 2009
Last Update
October 1 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Medisch Centrum Haaglanden
The Hague, Z-Holland, Netherlands, 2512va
2
Haga Ziekenhuis
The Hague, Z-Holland, Netherlands, 2545ch